The University of Chicago Header Logo

Connection

Arlene Chapman to Polycystic Kidney, Autosomal Dominant

Back to Details
This is a "connection" page, showing publications Arlene Chapman has written about Polycystic Kidney, Autosomal Dominant.
Arlene Chapman
Connection Strength
20.137
Polycystic Kidney, Autosomal Dominant
  1. Pregnancy in Autosomal Dominant Polycystic Kidney Disease. Adv Kidney Dis Health. 2023 Sep; 30(5):454-460.
    View in: PubMed
    Score: 0.835
  2. Polycystic Kidney Disease in the Real World. Kidney360. 2021 12 30; 2(12):1882-1883.
    View in: PubMed
    Score: 0.744
  3. Hypoxia-Inducible Factor 1a (HIF-1a), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease. Am J Nephrol. 2018; 47(4):228-230.
    View in: PubMed
    Score: 0.573
  4. Autosomal dominant polycystic kidney disease. CMAJ. 2017 11 13; 189(45):E1396.
    View in: PubMed
    Score: 0.559
  5. New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017 Dec; 13(12):750-768.
    View in: PubMed
    Score: 0.555
  6. A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 10 06; 12(10):1695-1698.
    View in: PubMed
    Score: 0.548
  7. Gastrointestinal Manifestations of Autosomal-Dominant Polycystic Kidney Disease. Clin Gastroenterol Hepatol. 2017 01; 15(1):17-24.
    View in: PubMed
    Score: 0.508
  8. The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol. 2017 01; 32(1):31-42.
    View in: PubMed
    Score: 0.499
  9. Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy? Am J Kidney Dis. 2015 Jun; 65(6):811-3.
    View in: PubMed
    Score: 0.471
  10. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015 Jul; 88(1):17-27.
    View in: PubMed
    Score: 0.465
  11. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014 Dec; 29(12):2194-201.
    View in: PubMed
    Score: 0.429
  12. The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic kidney disease. Kidney Int. 2012 May; 81(9):814-5.
    View in: PubMed
    Score: 0.381
  13. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012 Mar; 7(3):479-86.
    View in: PubMed
    Score: 0.375
  14. Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010 Mar; 17(2):153-63.
    View in: PubMed
    Score: 0.328
  15. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol. 2010 Jan; 5(1):102-9.
    View in: PubMed
    Score: 0.324
  16. Polycystic kidney disease: The cadence of kidney growth in ADPKD. Nat Rev Nephrol. 2009 Jun; 5(6):311-2.
    View in: PubMed
    Score: 0.311
  17. Renal volume in children with ADPKD: size matters. Clin J Am Soc Nephrol. 2009 Apr; 4(4):698-9.
    View in: PubMed
    Score: 0.307
  18. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol. 2009 Mar; 4(3):560-6.
    View in: PubMed
    Score: 0.306
  19. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008 Jul; 3(4):1197-204.
    View in: PubMed
    Score: 0.292
  20. Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD. Pediatr Nephrol. 2008 Jul; 23(7):1029-36.
    View in: PubMed
    Score: 0.284
  21. Autosomal dominant polycystic kidney disease: time for a change? J Am Soc Nephrol. 2007 May; 18(5):1399-407.
    View in: PubMed
    Score: 0.268
  22. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int. 2003 Nov; 64(5):1792-9.
    View in: PubMed
    Score: 0.211
  23. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003 Sep; 64(3):1035-45.
    View in: PubMed
    Score: 0.209
  24. Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation. Kidney Int. 2023 08; 104(2):334-342.
    View in: PubMed
    Score: 0.201
  25. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. Am J Kidney Dis. 2023 05; 81(5):517-527.e1.
    View in: PubMed
    Score: 0.199
  26. Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States. Clin J Am Soc Nephrol. 2022 07; 17(7):976-985.
    View in: PubMed
    Score: 0.192
  27. Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2022 03; 17(3):374-384.
    View in: PubMed
    Score: 0.188
  28. Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. PLoS One. 2021; 16(5):e0252479.
    View in: PubMed
    Score: 0.178
  29. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2020 12 31; 16(1):48-58.
    View in: PubMed
    Score: 0.174
  30. 'A sword of Damocles': patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open. 2020 10 10; 10(10):e038005.
    View in: PubMed
    Score: 0.171
  31. Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney Int. 2021 04; 99(4):977-985.
    View in: PubMed
    Score: 0.170
  32. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020 08 06; 5(15).
    View in: PubMed
    Score: 0.169
  33. Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. Am J Kidney Dis. 2021 02; 77(2):255-263.
    View in: PubMed
    Score: 0.169
  34. Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360. 2020 Jul; 1(7):648-656.
    View in: PubMed
    Score: 0.169
  35. Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2020 07; 31(7):1640-1651.
    View in: PubMed
    Score: 0.167
  36. Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. Am J Kidney Dis. 2020 09; 76(3):361-373.
    View in: PubMed
    Score: 0.166
  37. Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. Am J Kidney Dis. 2020 08; 76(2):213-223.
    View in: PubMed
    Score: 0.164
  38. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 2020 02; 97(2):370-382.
    View in: PubMed
    Score: 0.159
  39. Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2019 06 07; 14(6):823-833.
    View in: PubMed
    Score: 0.155
  40. Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology (Carlton). 2019 Dec; 24(12):1214-1224.
    View in: PubMed
    Score: 0.155
  41. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019 07; 96(1):159-169.
    View in: PubMed
    Score: 0.153
  42. Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 2019 05; 95(5):1253-1261.
    View in: PubMed
    Score: 0.153
  43. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course. BMC Nephrol. 2019 02 25; 20(1):66.
    View in: PubMed
    Score: 0.153
  44. Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol. 2018 12 27; 19(1):378.
    View in: PubMed
    Score: 0.151
  45. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 10; 29(10):2458-2470.
    View in: PubMed
    Score: 0.148
  46. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018 04 01; 33(4):645-652.
    View in: PubMed
    Score: 0.143
  47. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018 03 01; 33(3):477-489.
    View in: PubMed
    Score: 0.143
  48. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Am J Kidney Dis. 2018 05; 71(5):666-676.
    View in: PubMed
    Score: 0.141
  49. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade? Curr Hypertens Rev. 2018; 14(1):39-47.
    View in: PubMed
    Score: 0.141
  50. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2018 03; 93(3):691-699.
    View in: PubMed
    Score: 0.141
  51. ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. Am J Kidney Dis. 2018 02; 71(2):294-296.
    View in: PubMed
    Score: 0.140
  52. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials. 2017 Nov 23; 18(1):560.
    View in: PubMed
    Score: 0.140
  53. Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. Am J Kidney Dis. 2018 02; 71(2):225-235.
    View in: PubMed
    Score: 0.140
  54. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 02; 29(2):571-578.
    View in: PubMed
    Score: 0.140
  55. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 11 16; 377(20):1930-1942.
    View in: PubMed
    Score: 0.139
  56. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1857-1865.
    View in: PubMed
    Score: 0.139
  57. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1461-1469.
    View in: PubMed
    Score: 0.136
  58. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2017 Jun 01; 32(6):969-975.
    View in: PubMed
    Score: 0.135
  59. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2017 11; 92(5):1206-1216.
    View in: PubMed
    Score: 0.135
  60. Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant. 2017 03 01; 32(3):487-497.
    View in: PubMed
    Score: 0.133
  61. Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial. J Clin Pharmacol. 2017 07; 57(7):906-917.
    View in: PubMed
    Score: 0.133
  62. Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2017; 45(3):257-266.
    View in: PubMed
    Score: 0.132
  63. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev. 2017; 13(2):109-120.
    View in: PubMed
    Score: 0.132
  64. Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease. Am J Kidney Dis. 2017 03; 69(3):482-484.
    View in: PubMed
    Score: 0.131
  65. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2017 02; 91(2):493-500.
    View in: PubMed
    Score: 0.131
  66. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. J Am Soc Nephrol. 2017 May; 28(5):1592-1602.
    View in: PubMed
    Score: 0.131
  67. Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. Am J Kidney Dis. 2017 Feb; 69(2):210-219.
    View in: PubMed
    Score: 0.130
  68. Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease. Phys Med Biol. 2016 11 21; 61(22):7864-7880.
    View in: PubMed
    Score: 0.130
  69. Mutations in GANAB, Encoding the Glucosidase IIa Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet. 2016 06 02; 98(6):1193-1207.
    View in: PubMed
    Score: 0.126
  70. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016 05 06; 11(5):803-811.
    View in: PubMed
    Score: 0.124
  71. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 09; 27(9):2872-84.
    View in: PubMed
    Score: 0.123
  72. Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2016 Apr 07; 11(4):576-84.
    View in: PubMed
    Score: 0.123
  73. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant. 2016 11; 31(11):1887-1894.
    View in: PubMed
    Score: 0.122
  74. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis. 2015 Oct; 66(4):583-90.
    View in: PubMed
    Score: 0.118
  75. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015 Jul; 88(1):146-51.
    View in: PubMed
    Score: 0.116
  76. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2267-76.
    View in: PubMed
    Score: 0.114
  77. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2255-66.
    View in: PubMed
    Score: 0.114
  78. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):155-64.e6.
    View in: PubMed
    Score: 0.111
  79. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 Jan; 26(1):160-72.
    View in: PubMed
    Score: 0.110
  80. Novel methodology to evaluate renal cysts in polycystic kidney disease. Am J Nephrol. 2014; 39(3):210-7.
    View in: PubMed
    Score: 0.108
  81. Renal relevant radiology: radiologic imaging in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014 Feb; 9(2):406-15.
    View in: PubMed
    Score: 0.107
  82. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis. 2014 Feb; 63(2):214-26.
    View in: PubMed
    Score: 0.106
  83. Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. Am J Nephrol. 2013; 38(4):333-41.
    View in: PubMed
    Score: 0.105
  84. Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2013 Jul; 8(7):1089-97.
    View in: PubMed
    Score: 0.101
  85. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One. 2013; 8(1):e53016.
    View in: PubMed
    Score: 0.100
  86. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20; 367(25):2407-18.
    View in: PubMed
    Score: 0.099
  87. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int. 2012 Apr; 81(8):784-90.
    View in: PubMed
    Score: 0.093
  88. Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012 Mar; 81(6):577-85.
    View in: PubMed
    Score: 0.093
  89. Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2508-15.
    View in: PubMed
    Score: 0.091
  90. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2499-507.
    View in: PubMed
    Score: 0.091
  91. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011 May; 57(5):692-9.
    View in: PubMed
    Score: 0.088
  92. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Mar; 6(3):640-7.
    View in: PubMed
    Score: 0.086
  93. Renal CD14 expression correlates with the progression of cystic kidney disease. Kidney Int. 2010 Sep; 78(6):550-60.
    View in: PubMed
    Score: 0.084
  94. MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol. 2009 Apr; 4(4):719-25.
    View in: PubMed
    Score: 0.077
  95. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int. 2008 Dec; 74(11):1468-79.
    View in: PubMed
    Score: 0.074
  96. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007 Jul; 18(7):2143-60.
    View in: PubMed
    Score: 0.068
  97. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2007 Jan; 2(1):112-20.
    View in: PubMed
    Score: 0.065
  98. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2006 Nov; 17(11):3013-9.
    View in: PubMed
    Score: 0.065
  99. Volume progression in polycystic kidney disease. N Engl J Med. 2006 May 18; 354(20):2122-30.
    View in: PubMed
    Score: 0.063
  100. Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol. 2006 Mar; 17(3):854-62.
    View in: PubMed
    Score: 0.062
  101. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis. 2005 Dec; 46(6):1058-64.
    View in: PubMed
    Score: 0.061
  102. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006 Jan; 1(1):64-9.
    View in: PubMed
    Score: 0.061
  103. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006 Jan; 1(1):148-57.
    View in: PubMed
    Score: 0.061
  104. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int. 2003 Dec; 64(6):2214-21.
    View in: PubMed
    Score: 0.053
  105. Cystic and inherited kidney diseases. Am J Kidney Dis. 2003 Dec; 42(6):1305-17.
    View in: PubMed
    Score: 0.053
  106. Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int. 2003 May; 63(5):1824-30.
    View in: PubMed
    Score: 0.051
  107. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002 Jul; 13(7):1733-9.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.